

Listing of the Claims

This listing of claims will replace all prior versions, and listings of claims in the application.

1. (Cancelled)

2. (Currently amended) An anti-LRP-A β molecule comprising, an A β binding domain, and an LRP binding domain, or a pharmaceutically acceptable salt thereof; wherein the anti-LRP-A β molecule does not comprise SEQ ID NO:4.

3. (Original) The anti-LRP-A β molecule of claim 2, wherein said molecule is a peptide, or a pharmaceutically acceptable salt thereof.

4. (Currently amended) An anti-LRP-A β peptide comprising:

- (a) an A β binding domain comprising 10-50 contiguous residues of SEQ ID NO:6; and
- (b) an LRP binding domain comprising 10-50 contiguous residues of SEQ ID NO:8, wherein said 10-50 contiguous residues of SEQ ID NO:8 encompass residues 1366-1392,

or a pharmaceutically acceptable salt thereof;

wherein the anti-LRP-A β peptide does not comprise SEQ ID NO:4.

5. (Currently amended) An anti-LRP-A β peptide comprising:

- (a) an A β binding domain having an amino acid sequence selected from the group consisting of SEQ ID NO:6, SEQ ID NO:12, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24, and SEQ ID NO:26; and
- (b) an LRP binding domain having the amino acid sequence of SEQ ID NO:10,

or a pharmaceutically acceptable salt thereof;

wherein the anti-LRP-A β peptide does not comprise SEQ ID NO:4.

6. (Currently amended) An anti-LRP-A β peptide comprising:

- (a) an A β binding domain having an amino acid sequence selected from the group consisting of SEQ ID NO:12, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24, and SEQ ID NO:26; and
- (b) an LRP binding domain comprising 10-50 contiguous residues of SEQ ID NO:8,

or a pharmaceutically acceptable salt thereof;

wherein the anti-LRP-A β peptide does not comprise SEQ ID NO:4.

7. (Original) The anti-LRP-A β peptide of claims 4, 5 or 6, wherein said A β binding domain is connected to said LRP binding domain by a peptide bond.

8. (Original) The anti-LRP-A β peptide of claims 4, 5 or 6, wherein said A β binding domain is connected to said LRP binding domain by a linker.

9. (Currently amended) The anti-LRP-A β peptide of claim 8, wherein said linker is selected from the group consisting of a peptide, ~~or~~ and polyethylene glycol.

10. (Previously presented) The anti-LRP-A β peptide of claim 8, wherein said linker comprises 1-20 glycine residues.

11. (Cancelled)

12. (Currently amended) An anti-LRP-A β peptide comprising a polypeptide having the sequence of SEQ ID NO:14, or a pharmaceutically acceptable salt thereof; wherein the anti-LRP-A β peptide does not comprise SEQ ID NO:4.

13. (Currently amended) An anti-LRP-A β peptide comprising:

- (a) an A β binding domain having an amino acid sequence selected from the group consisting of SEQ ID NO:6, SEQ ID NO:12, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24, and SEQ ID NO:26;
- (b) an LRP binding domain having the amino acid sequence of SEQ ID NO:10; and

(c) a linker connecting said A β binding domain to said LRP binding domain;

wherein the anti-LRP-A β peptide does not comprise SEQ ID NO:4.

14 - 26. (Cancelled)

27. (Original) A pharmaceutical composition comprising an anti-LRP-A β molecule, and one or more pharmaceutically acceptable carriers.

28. (Currently amended) A pharmaceutical composition comprising the anti-LRP-A β peptide of claims 2, 4, 5, 6, or 13, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers.

29. (Currently amended) A pharmaceutical composition comprising an anti-LRP-A β peptide having an amino acid sequence selected from the group consisting of SEQ ID NO:4 ~~or~~ and SEQ ID NO:14, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers.

30 - 50. (Cancelled)

51 - 64. (Cancelled)

65 - 76. (Cancelled)